Clinical Trials
22 trialsNCT00600496 2026-05-27
A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
AstraZeneca
Phase 1 Completed
NCT03403049 2026-04-13
Carbon Ion Radiation Therapy for Locally Advanced Pancreatic Cancer
Montefiore Medical Center
Phase 1 Completed
NCT02099058 2025-08-14
A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors
AbbVie
Phase 1 Active not recruiting
NCT06161558 2025-07-16
Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Withdrawn
NCT00708448 2025-02-13
Early Prediction of Therapeutic Response to Targeted Therapy in Stage IIIB/IV or Recurrent Lung Cancer Patients
University of Utah
Phase 1 Completed
NCT01594398 2021-11-19
ENCORE110
Syndax Pharmaceuticals
Phase 1 Completed
NCT01199068 2021-05-13
CS-7017 in Combination With Erlotinib in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)
Daiichi Sankyo
Phase 1 Completed
NCT00848718 2019-11-12
MK-2206-003
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT01545947 2019-11-12
Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
Celgene
Phase 1 Completed
NCT01472016 2017-11-21
Study of ABT-700 in Subjects With Advanced Solid Tumors
AbbVie
Phase 1 Completed
NCT01192165 2017-11-13
Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel
GlaxoSmithKline
Phase 1 Completed
NCT01482377 2017-01-27
A Study of RO5479599 Alone or in Combination With Cetuximab or Erlotinib in Participants With Metastatic and/or Locally Advanced Malignant Human Epidermal Growth Factor Receptor (HER3) Expressing Solid Tumors of Epithelial Cell Origin
Hoffmann-La Roche
Phase 1 Completed
NCT00811993 2016-11-02
A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors
Hoffmann-La Roche
Phase 1 Terminated
NCT00705874 2016-07-21
Study of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma
Progen Pharmaceuticals
Phase 1 Completed
NCT00207077 2015-10-28
Study of Cetuximab in Combination With Tarceva in Patients With Solid Tumors
Eli Lilly and Company
Phase 1 Completed
NCT01727869 2015-04-06
Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of Cancer
Regeneron Pharmaceuticals
Phase 1 Completed
NCT00884845 2014-03-26
Trial of PM02734 Administered in Combination With Erlotinib in Patients With Advanced Malignant Solid Tumors
PharmaMar
Phase 1 Completed
NCT00725634 2014-01-27
P05538
AVEO Pharmaceuticals, Inc.
Phase 1 Completed
NCT00591383 2012-07-19
Phase I Study of Indibulin in Combination With Erlotinib in Advanced Solid Tumors
Alaunos Therapeutics
Phase 1 Unknown
NCT00692640 2012-03-23
Safety Study of XL147 (SAR245408) in Combination With Erlotinib in Adults With Solid Tumors
Sanofi
Phase 1 Completed
NCT00777699 2012-02-03
Safety Study of XL765 (SAR245409) in Combination With Erlotinib in Adults With Solid Tumors
Sanofi
Phase 1 Completed
NCT00603356 2011-09-27
Phase I Study of OSI-930 and Erlotinib in Cancer Tumors
Astellas Pharma Inc
Phase 1 Completed